ADVFN US – Market Content Editor

Glucotrack has completed its business combination with Lōkahi Therapeutics, transforming the company into a Lōkahi-controlled public platform focused on acquiring and advancing healthcare assets while retaining its continuous blood glucose monitoring business as a standalone subsidiary. Key Investor Takeaways Why GCTK Stock Is in Focus Glucotrack (NASDAQ:GCTK) announced the completion of its previously announced business…

Dateline Resources reported widespread rare earth mineralisation from initial field sampling at its Music Valley project in California, with all collected rock samples returning anomalous rare earth results and the highest assay reaching 7.13% total rare earth oxides (TREO). Key Investor Takeaways Why DTREF Stock Is in Focus Dateline Resources (USOTC:DTREF) announced encouraging initial exploration…

Phio Pharmaceuticals has strengthened the intellectual property protection surrounding its INTASYL® gene silencing platform after receiving multiple favorable patent decisions across the United States, Canada, and Japan. Key Investor Takeaways Why PHIO Stock Is in Focus Phio Pharmaceuticals (NASDAQ:PHIO) announced multiple patent milestones that further expand protection for its proprietary INTASYL® gene silencing technology. The…

Premier Graphene and HGI Industrial Technologies have completed the first delivery under a 1,600-unit contract with Mexico’s Secretariat of National Defense (SEDENA), marking another operational milestone as the companies pursue additional government opportunities. Key Investor Takeaways Why BIEI Stock Is in Focus Premier Graphene (USOTC:BIEI) and its manufacturing partner, HGI Industrial Technologies, announced the successful…

Genentech has received FDA Priority Review for Gazyva in primary membranous nephropathy, bringing the therapy closer to potentially becoming the first FDA-approved treatment for the rare autoimmune kidney disease. Key Investor Takeaways Why RHHBY Stock Is in Focus Genentech, a member of the Roche Group (USOTC:RHHBY), announced that the U.S. Food and Drug Administration has…

Xeriant has secured a U.S. patent covering its proprietary fire-resistant composite technology, strengthening the intellectual property behind its NEXBOARD construction materials platform and supporting future commercialization efforts. Key Investor Takeaways Why XERI Stock Is in Focus Xeriant (USOTC:XERI) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,679,047 covering the company’s…

BioAdaptives has introduced XcellaraHeart™, a new cardiovascular wellness supplement built on its Xcellara™ platform, with commercial availability scheduled to begin on August 1, 2026. Key Investor Takeaways Why BDPT Stock Is in Focus BioAdaptives (USOTC:BDPT) announced the upcoming commercial launch of XcellaraHeart™, a cardiovascular wellness formula designed to combine its existing Xcellara™ stem/progenitor cell mobilization…

Victory Marine Holdings reported a significant reduction in convertible debt alongside continued commercialization of its beverage and wellness platform, marking the first full quarter of execution following its March 2026 reverse merger. Key Investor Takeaways Why VMHG Stock Is in Focus Victory Marine Holdings (USOTC:VMHG), through its operating subsidiary Dunn & Groux Beverage Holdings, highlighted…

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor Takeaways Why CRDF Stock Is in Focus Cardiff Oncology (NASDAQ:CRDF) announced definitive agreements for a registered direct offering expected to generate approximately $10 million…

Rekor Systems’ preliminary second-quarter results point to stronger operating performance following a broad restructuring effort, while management now expects to reach Adjusted EBITDA profitability during the second half of 2026. Key Investor Takeaways Why REKR Stock Is in Focus Rekor Systems (NASDAQ:REKR) reported preliminary, unaudited second-quarter 2026 financial results that suggest meaningful progress in its…